In re Vioxx Products Liability Litigation

889 F. Supp. 2d 857, 2012 WL 4097200
District Court, E.D. Louisiana·Decided September 17, 2012·No. MDL No. 1657·Published·Cited by 4 cases

Opinion

[858]*858 ORDER & REASONS

ELDON E. FALLON, District Judge.

The Court has pending before it Merck’s motion for summary judgment with respect to Plaintiff Sandra Elliott (Rec. Doc. 63872) and Plaintiff Elliott’s motion for an extension of time to respond to Merck’s motion (Rec. Doc. 64004). The Court has reviewed the briefs and the applicable law and now issues this Order and Reasons.

I. BACKGROUND

To put this matter in perspective, a brief review of this litigation is appropriate. This multidistrict products liability litigation involves the prescription drug Vioxx, known generically as Rofecoxib. Merck, a New Jersey corporation, researched, designed, manufactured, marketed and distributed Vioxx to relieve pain and inflammation resulting from osteoarthritis, rheumatoid arthritis, menstrual pain, and migraine headaches. On May 20, 1999, the Food and Drug Administration approved Vioxx for sale in the United States. Vioxx remained publicly available until September 30, 2004, when Merck withdrew it from the market after data from a clinical trial known as APPROVe indicated that the use of Vioxx increased the risk of cardiovascular thrombotic events such as myocardial infarction (heart attack) and ischemic stroke. Thereafter, [859]*859thousands of individual suits and numerous class actions were filed against Merck in state and federal courts throughout the country alleging various products liability, tort, fraud, and warranty claims. On November 9, 2007, after extensive discovery, pretrial proceedings, and a number of bellwether trials, the parties announced a $4.85 billion Master Settlement Agreement that eventually resolved over 99% of Vioxx claims.

This remaining personal injury case arises out of various alleged injuries to Plaintiff Sandra Elliott. Elliott is a resident of California who alleges that she took Vioxx from October 2002 to May 2004. Elliott claims that as a result of using Vioxx, she experienced congestive heart failure on May 12, 2003. Elliott filed suit in California state court in 2006. The case was subsequently removed to the Eastern District of California and transferred to this MDL. Elliott later enrolled in the Vioxx Resolution Program, but her claim was found ineligible by the Claims Administrator, so she signed a Future Evidence Stipulation and continued to pursue her case in court. Although Elliott’s case was at one point dismissed with prejudice for failure to comply with Pretrial Order 43 (Rec. Doc. 26346), it was later reinstated with Merck’s consent (Rec. Doc. 46845).

II. PRESENT MOTIONS

Merck now moves for summary judgment with respect to Elliott’s claims. (Rec. Doc. 63959). Merck claims that Elliott failed to disclose her lawsuit against Merck when she filed for Chapter 7 bankruptcy in July 2009. Therefore, Merck argues that Elliott’s claims against Merck should now be dismissed under the doctrine of judicial estoppel. In response, Elliott moves for an extension of time to respond to Merck’s motion. (Rec. Doc. 64004). Elliott requests additional time in order to amend her bankruptcy petition to include her Vioxx claim.

III. LAW AND ANALYSIS

A. Summary Judgment Standard

Summary judgment is appropriate if the moving party can show “there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(a). Under Federal Rule of Civil Procedure 56(c), the moving party bears the initial burden of “informing the district court of the basis for its motion, and identifying those portions of [the record] which it believes demonstrate the absence of a genuine issue of material fact.” Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). When the moving party has met its Rule 56(c) burden, the nonmovant cannot survive a motion for summary judgment by resting on the mere allegations of its pleadings. See Prejean v. Foster, 227 F.3d 504, 508 (5th Cir.2000). “The mere existence of a scintilla of evidence in support of the plaintiffs position will be insufficient; there must be evidence on which the jury could reasonably find for the plaintiff.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 253, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). In deciding a summary judgment motion, the court reviews the facts drawing all reasonable inferences in the light most favorable to the nonmovant. Id. at 255, 106 S.Ct. 2505.

B. Judicial Estoppel

“Judicial estoppel is a common law doctrine that prevents a party from assuming inconsistent positions in litigation.” In re Superior Crewboats, Inc., 374 F.3d 330, 334 (5th Cir.2004). “[T]he Bankruptcy Code and Rules impose upon bankruptcy debtors an express, affirmative duty to disclose all assets, including contingent and unliquidated claims.” In re [860]*860Coastal Plains, Inc., 179 F.3d 197, 207-08 (5th Cir.1999). Thus, judicial estoppel can bar a plaintiff from proceeding with a claim when he or she failed to disclose that claim in a bankruptcy petition. There are three requirements for judicial estoppel to apply: “(1) [T]he party is judicially es-topped only if its position is clearly inconsistent with the previous one; (2) the court must have accepted the previous position; and (3) the non-disclosure must not have been inadvertent.” Superior Crewboats, 374 F.3d at 335. A nondisclosure is considered inadvertent “only when, in general, the debtor either lacks knowledge of the undisclosed claims or has no motive for their concealment.” Coastal Plains, 179 F.3d at 210.

C. Analysis

Merck asserts that all three requirements listed above are met in Elliott’s case. Merck argues that Elliott’s omission of her Vioxx-related claims from her bankruptcy filing was “tantamount to a representation that no such elaim[s] existed,” Superior Crewboats, 374 F.3d at 335, and this representation was accepted by the bankruptcy court when it adopted Elliott’s position that she had no claims. Merck argues that the disclosure was not inadvertent because Elliott was aware of her claims — which, at the time of her bankruptcy filing, she had already been pursuing for approximately three years — and that Elliott had a motive to conceal her claims because by doing so, she would be able to profit from them directly, rather than having to distribute the funds to her creditors.

Elliott responds with several arguments, focusing mainly on the element of inadvertence. Generally, she argues that “there is a genuine dispute about whether [she] made a good faith mistake,” rather than attempting to game the system and keep the proceeds of her Vioxx claim for herself. (Pl.’s Supp. Opp., Rec. Doc. 64091 at 5).

Free access — add to your briefcase to read the full text and ask questions with AI

In re Vioxx Products Liability Litigation, 889 F. Supp. 2d 857, 2012 WL 4097200 (E.D. La. 2012).

889 F. Supp. 2d 857 (In re Vioxx Products Liability Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related